Healthcare

The European Healthcare Innovation Leadership Network (EHILN) focused on advancing European healthcare innovation to ensure support of novel clinical development programs and patient access to treatments in an era of severe budgetary pressures.  From 2006-2012, EHILN addressed heightened uncertainty of healthcare access during financial austerity in Europe by enabling candid conversations across industry and government agencies, exploring new approaches to payment and outcome models, and designing and piloting a new regulatory and reimbursement approach – the parallel scientific advice process.

Specifically, EHILN catalyzed six multistakeholder drug development pilots, enabling regulators, health technology assessors, payers, patients, and medical experts from the EU to advise pharmaceutical companies on development decisions regarding Phase 1 to Phase 3 products. These pilots paved the way for the eventual institutionalization of this approach in Europe,  known today as the Parallel EMA/EUnetHTA 21 Joint Scientific Consultations, whereby payers and regulators jointly assess the efficacy, safety, and clinical utility of drugs to advance the development process.  Many pilot participants praised the process as providing both a safe, neutral forum and a disciplined, thoughtful approach that acknowledged the key issues and positions of participants.

EHILN also designed specific working groups to develop disease-specific value frameworks in diabetes and breast cancer, and examined multistakeholder platforms for accelerating the innovation and delivery of Alzheimer’s treatments.   

Tapestry’s work in EHILN has been acknowledged in academic journals, government and other forums and institutions.